Area of research
Cancer Research · Oncology
Research interest
Research interests include Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Acute Myeloid Leukemia Research, and Lung Cancer Treatments and Mutations.
Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy.
Evolutionary fingerprints of epithelial-to-mesenchymal transition.
Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial.
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial.
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation
The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers
The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers.
Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors.
Author Correction: Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.
Supplementary Figures from Single-Cell Profiling of CD8<sup>+</sup> T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion
Supplementary Tables S1-15 from Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2<sup>C134W</sup> Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors
Table S1-7 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
Figure S3 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
Data from Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors
Data from Single-Cell Profiling of CD8<sup>+</sup> T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion
Supplementary Figures S1-16 from Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2<sup>C134W</sup> Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors
Supplementary Figures 1-6 from Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors
Supplementary Table 4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Supplementary Figure S6 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Supplementary Figure S8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Supplementary Table 3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Figure S1 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
Supplementary Figure S2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Supplementary Figure S1 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Supplementary Table 5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma